Aptar Group’s Aptar Digital Health has partnered with blood collection solutions provider Tasso to facilitate blood sample collection for multiple indications including chronic conditions and oncology.

Under the partnership, Aptar Digital Health’s end-users will have access to Tasso’s blood collection devices.

The collaboration intends to improve patient care via a streamlined and integrated experience.

It is expected to deliver clinical value to patients with real-world deployment and increased use of new technologies by patients, providers, and pharmaceutical organisations, Aptar said.

Tasso’s blood collection devices will be accessible to patients recruited in Aptar Digital Health’s randomised-clinical trials and real-world studies.

In addition, the device will be available to life science firms with whom Aptar Digital Health partners to develop digital health solutions like digital therapeutics, disease management platforms, and digital patient support programmes (PSPs).

Aptar Digital Health president Sai Shankar said: “At Aptar Digital Health, we are committed to leveraging cutting-edge technology to enhance the patient experience.

“The collaboration with Tasso to offer their technologies is a further step towards simplifying the patient journey.”

According to Aptar, patients will gain access to the Tasso+ and Tasso-M20 blood collection devices.

The Tasso+ is a blood lancet that has Class 2 510(k)-clearance from the US Food and Drug Administration (FDA).

The Tasso-M20 is a CE-marked device that collects volumetrically-controlled dried whole blood samples from patients for delivery to the laboratory.

Enrolled patients can keep track of their illnesses and symptoms using the digital health app offered by Aptar Digital Health. When a blood test is required by the doctor, samples will be taken with Tasso’s devices and sent for analysis, Aptar said.

Tasso CEO and co-founder Ben Casavant said: “Our proprietary technology allows for easy, virtually-painless remote sample blood collection, creating an easier and more pleasant experience for patients and shifting how clinical research can be executed.”

“We are dedicated to expanding access to patient-centric care, reducing barriers and supporting greater adoption of decentralised clinical trials.”